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Objectives:Methicillin-resistant Staphylococcus aureus (MRSA) is an important global health problem. MRSA resist-
ance to b-lactam antibiotics is mediated by the mecA or mecC genes, which encode an alternative penicillin-
binding protein (PBP) 2a that has a low affinity tob-lactam antibiotics. Detection ofmecgenes or PBP2a is regarded
as the gold standard for the diagnosis of MRSA. We identified four MRSA isolates that lacked mecA ormecC genes,
but were still phenotypically resistant to pencillinase-resistant b-lactam antibiotics.
Methods:The four humanS. aureus isolates were investigated by whole genome sequencing and a range of pheno-
typic assays.
Results: We identified a number of amino acid substitutions present in the endogenous PBPs 1, 2 and 3 that were
found in the resistant isolates but were absent in closely related susceptible isolates and which may be the basis of
resistance. Of particular interest are three identical amino acid substitutions in PBPs 1, 2 and 3, occurring independ-
ently in isolates from at least two separate multilocus sequence types. Two different non-conservative substitu-
tions were also present in the same amino acid of PBP1 in two isolates from two different sequence types.
Conclusions: This work suggests that phenotypically resistant MRSA could be misdiagnosed using molecular
methods alone and provides evidence of alternative mechanisms for b-lactam resistance in MRSA that may
need to be considered by diagnostic laboratories.
Keywords: b-lactams, MRSA, mecA, mecC
Introduction
b-Lactam antibiotics work by acylation of the transpeptidase
domain active site of penicillin-binding proteins (PBPs), blocking
access to their substrate and preventing cross-linking of peptidogly-
canstrands duringcellwall synthesis. Initially, resistancetopenicillin
in Staphylococcus aureus was mediated by the expression of a
b-lactamase enzyme, which breaks down penicillin. Since the intro-
duction of methicillin, a semi-syntheticb-lactamase-resistant peni-
cillin, in 1961, methicillin-resistant S. aureus (MRSA) has emerged
that is resistant to the majority of b-lactam antibiotics.1 Resistance
to b-lactams in MRSA is mediated by the acquisition of the mecA
gene, which encodes an alternative PBP2a, which has low affinity
for b-lactam antibiotics and enables the bacteria to assemble the
cell wall in the presence of the drug.2,3 More recently, a divergent
form of the mecA gene, known as mecC (previously mecALGA251),
was identified in isolates of S. aureus from both animals and
humans.4 S. aureus isolates with other types of resistance to
b-lactams have been described and are known as borde-
rline oxacillin-resistant S. aureus (BORSA) or intrinsically resistant
S. aureus.5,6 Resistance in some BORSA isolates is attributed to
the presence or overexpression of b-lactamase enzymes,6,7 while
in intrinsically resistant and some BORSA isolates it is mediated
by chromosomal mutations.5,8,9 Furthermore, in vitro studies gen-
erating b-lactam-resistant isolates under the selection of
b-lactam antibiotics have also identified a number of other
genes able to mediate intrinsic b-lactam resistance.8,10,11 Here,
we report four clinical MRSA isolates from three multilocus
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sequence types (STs) that are resistant to b-lactamase-resistant
penicillins, but lack both mecA and mecC. This demonstrates that
mec-negative MRSA isolates with resistance to multiple
b-lactams may be responsible for human infection, but may be
misclassified as methicillin susceptible based on detection of
mecA/C or PBP2a, potentially leading to treatment failure.
Methods
Isolates were grown on blood agar (Oxoid, UK) and in tryptone soya broth
(TSB) at 378C. A list of the isolates used in this study is shown in Table 1.
Antimicrobial susceptibility testing was performed using disc susceptibil-
ity testing according to BSAC criteria (BSAC Methods for Antimicrobial Sus-
ceptibility Testing, version 11.1, May 2012). Strains NCTC 6571, NCTC
12493, LGA251 and NCTC 29213 acted as susceptible, mecA resistant,
mecC resistant and b-lactamase overproducer controls, respectively. Iso-
lates were tested for b-lactamase production by using b-lactamase
(nitrocefin) identification sticks (Oxoid, UK) according to the manufac-
turer’s instructions. The cloverleaf assay was carried out as previously
described.12 Genomic DNA was extracted from overnight cultures grown
in TSB at 378C using a MasterPure Gram-positive DNA Purification Kit
(Cambio, UK). Illumina library preparation and Hi-Seq sequencing were
carried out as previously described.13 Orthologous proteins were identi-
fied using BLAST.
Results
We identified fourmecA/C-negative isolates (XB84, 85, 86 and 87)
from the Scottish MRSA Reference Laboratory that exhibited re-
sistance to penicillinase-resistant b-lactams. All four were iso-
lated from human wound infections in Scotland and belonged
to STs 15, 1, 15 and 8, respectively. All four isolates exhibited re-
sistance to oxacillin, cefoxitin and penicillin by both Etest and
disc diffusion assays (BSAC, version 11.1) (Table 1) (except XB84,
which was at the oxacillin Etest breakpoint). All four isolates
also had an MIC of ceftriaxone of .32 mg/L (Table 1). Three iso-
lates (XB84, 85 and 87) were positive for b-lactamase production
as measured by b-lactamase (nitrocefin) sticks and a cloverleaf
assay. To further elucidate the molecular basis of resistance, the
four isolates underwent whole genome sequencing. This con-
firmed that none of the isolates harboured a mecA or mecC
gene, or any coding sequence resembling a putative mec gene
homologue. Bioinformatic analysis confirmed that the isolates
(XB84, 85 and 87) that were positive for b-lactamase production
had ablaZgene and that XB86, which was negative forb-lactamase
production, lackedblaZ (Table 1).Furtheranalysis of theblaZgenes in
each isolate showed that XB87 had a type A blaZ gene, while both
XB84 and XB85 had an identical (100% nucleotide identity) type
C blaZ gene.14
We next used BLAST to identify further isolates in our
sequenced genome collection that shared 100% nucleotide iden-
tity across the entire b-lactamase (bla) locus (blaZ-blaI-blaR) for
the two blaZ genes (types A and C). We identified three isolates
with a type A blaZ gene and 12 isolates with a type C blaZ gene
and tested them for phenotypic resistance to oxacillin and cefox-
itin (data not shown). No association was found between the
presence of either type of blaZ gene and resistance. To further
investigate the role of blaZ in the resistant isolates, we repeated
the disc diffusion assays in the presence of clavulanic acid
(a b-lactamase inhibitor) at ratios of 2:1 and 1:1, Ta
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antibiotic :clavulanic acid. No major reduction was seen in the
zones of inhibition of oxacillin, cefoxitin or penicillin in combin-
ation with clavulanic acid at either 2 : 1 or 1 : 1, suggesting
that b-lactamase production was not mediating resistance
(Table 1).
In addition to PBP2a and b-lactamase, five other proteins
(PBP2, PBP4, GdpP, YjbH and AcrB) have been reported previously
to be associated with b-lactam resistance in S. aureus.8 – 11,15 – 17
We screened the genome sequences of the four resistant isolates
for the presence of previously reported mutations, but none was
found in our isolates. Next, we compared the sequences for these
same five proteins from the four resistant isolates with a panel of
susceptible isolates belonging to the same STs (ST1, 10 isolates;
ST8, 4 isolates; and ST15, 2 isolates) (data not shown). In the
comparison, we also included the two other endogenous PBPs
(PBP1 and PBP3) on the basis that these are also bound by
b-lactam antibiotics.17,18 We found a small number of amino
acid substitutions to be present in PBP1, PBP2, PBP3 and YjbH in
one or more of the resistant isolates, but absent in the susceptible
counterparts (Table 2). Interestingly, we found three separate
residues with substitutions that were present in at least two iso-
lates from different STs, suggestive of homoplasy (independent
evolution of the same trait). First, a His-499Tyr substitution in
the transpeptidase domain of PBP1 was present in three isolates
from three different STs: XB85 (ST1), XB86 (ST15) and XB87 (ST8)
(Table 2). Second, a Thr-552IIe substitution in the transpepti-
dase domain of PBP2 was found in three isolates from two STs:
XB84 (ST15), XB86 (ST15) and XB87 (ST8). Third, isolates XB84
(ST15), XB85 (ST1) and XB86 (ST15) all shared the same
Ser-634Phe substitution in the transpeptidase domain of
PBP3 (Table 2). Fourth, we identified two different non-
conservative amino acid substitutions at the same position in
the transpeptidase domain of PBP1, a Tyr-336Asn substitution
in XB84 (ST15) and a Tyr-336Cys substitution in XB85 (ST1). A
number of single substitutions were also present in one of the re-
sistant isolates that were absent in the susceptible isolates of the
same ST (Table 2). Two further substitutions were present in PBP2:
a Thr-31Met substitution in XB85 and an Asp-156Tyr substi-
tution in the transpeptidase domain of isolate XB86. XB85 also had
a Thr-371IIe substitution in the transpeptidase domain of PBP1
(Table 2). Except for MRSA strain CM05 (accession: AMAB00000000),
which had the Asp-156Tyr mutation in PBP2, we were unable to
find any genomes in the NCBI/EMBL databases containing the same
substitutions.
Discussion
In this work we have identified MRSA isolates belonging to three
STs, which unlike BORSA strains are resistant to both oxacillin and
cefoxitin. This resistance does not appear to be mediated by hyper-
production of a b-lactamase and we have identified a number of
novel substitutions in the transpeptidase domains of PBPs 1, 2
and 3 that we hypothesize could mediate this resistance. The
transpeptidase domains of PBPs are the target ofb-lactam antibio-
tics and substitutions in the transpeptidase domain of PBP2 have
been shown previously to reduce the acylation efficacy of PBP2
by b-lactams and thus provide some degree of resistance.8,15
Given the small number of isolates in this study and that our tar-
geted search for mutations might have excluded other genes
involved in resistance, further experimental work is necessary to
characterize the contribution of the novel PBP substitutions to
b-lactam resistance. Mutations in PBP1 and PBP3 have not been
implicated previously in S. aureus resistance; however, in Staphylo-
coccus lugdunensis, a tetrapeptide duplication in the transpepti-
dase domain of PBP1A/B has been shown to be associated with
increased b-lactam resistance.19 Currently, mec gene-negative
MRSA isolates are not widely reported, but it is important to charac-
terize the basis for resistance in these isolates, especially for clinical
laboratories that rely on the molecular detection ofmecA/Cand/or
PBP2a as the gold standard for MRSA detection. Furthermore,
PBP2a has been highlighted as an attractive target for drug devel-
opment20 and should PBP2a-targeted inhibitors become available,
it is important to understand alternative mechanisms for S. aureus
to develop resistance to b-lactams. Finally, it is clear that there are
multiple distinct mechanisms for b-lactam resistance in S. aureus
and these need to be taken into consideration bydiagnostic labora-
tories.
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